0001754249-20-000001.txt : 20200204 0001754249-20-000001.hdr.sgml : 20200204 20200204211632 ACCESSION NUMBER: 0001754249-20-000001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200131 FILED AS OF DATE: 20200204 DATE AS OF CHANGE: 20200204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Welch David F CENTRAL INDEX KEY: 0001399122 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-49908 FILM NUMBER: 20576165 MAIL ADDRESS: STREET 1: C/O INFINERA CORPORATION STREET 2: 140 CASPIAN COURT CITY: SUNNYVALE STATE: CA ZIP: 94089 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytoDyn Inc. CENTRAL INDEX KEY: 0001175680 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 753056237 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 BUSINESS ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 BUSINESS PHONE: 360-980-8524 MAIL ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 FORMER COMPANY: FORMER CONFORMED NAME: CYTODYN INC DATE OF NAME CHANGE: 20031114 FORMER COMPANY: FORMER CONFORMED NAME: REXRAY CORP DATE OF NAME CHANGE: 20020617 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2020-01-31 0 0001175680 CytoDyn Inc. CYDY 0001399122 Welch David F 1111 MAIN STREET, SUITE 600 VANCOUVER WA 98660 1 0 0 0 Series D Convertible Preferred Stock 0.8 2020-01-31 4 P 0 1000 1000 A 2020-01-31 Common Stock 1250000 1000 I See footnote Warrants 1 2020-01-31 4 P 0 500000 A 2020-01-31 2025-01-31 Common Stock 500000 500000 I See footnote The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein. The preferred stock has no expiration date. The reporting person purchased units, each consisting of 1 share of preferred stock and warrants to purchase 500 shares of common stock, at a purchase price of $1,000 for each unit. /s/ Michael D. Mulholland, as attorney-in-fact 2020-02-04